Omri Amirav-Drory

Omri Amirav-Drory is a board member at Mana.bio. Omri was previously the CEO of resistanceBio, a Talus Bio, La Jolla Labs, Mana.bio, PANGEA Therapeutics, Pepper Bio, Nanocarry Therapeutics, Gilboa Therapeutics, and NFX.

Omri Amirav-Drory has a postdoctoral in Biochemistry and Molecular Biology from Stanford University, a Doctor of Philosophy (Ph.D.) in Biochemistry from Tel Aviv University, and a Bachelor of Science - BS in Biochemistry and Molecular Biology from Tel Aviv University.